Nov 2, 4:07 PM ET
BioMarin Pharmaceutical reported third-quarter 2026 total revenues of $1.025 billion, a 32% increase year-over-year, driven by contributions from acquired products including GALAFOLD and POMBILITI plus OPFOLDA. However, the company reported a GAAP net loss of $123 million due to acquisition-related expenses and IPR&D charges, and lowered its full-year 2026 Non-GAAP Diluted EPS guidance to a range of $2.80 to $3.10.
- Third-quarter 2026 total revenues rose 32% year-over-year to $1.025 billion.
- GAAP net loss widened to $123 million for the third quarter ended September 30, 2026, compared to a net loss of $31 million a year earlier.
- Full-year 2026 Non-GAAP Diluted EPS guidance was revised to between $2.80 and $3.10, down from prior expectations.
- The FDA set a PDUFA target action date of May 30, 2027, for VOXZOGO in hypochondroplasia.
Read the filing on SEC.gov ↗
Oct 6, 4:22 PM ET
BioMarin said its third-quarter 2026 results will include about $283 million of acquired in-process R&D expense tied to its Alesta Therapeutics acquisition, completed August 31, 2026. The company estimates the charges reduce both GAAP and non-GAAP diluted EPS by about $1.50 for the quarter and about $1.55 for the full year, and it will update full-year 2026 guidance with its third-quarter results.
- Q3 2026 pre-tax IPR&D charge of approximately $283 million, an unfavorable EPS impact of about $1.50
- Full-year 2026 pre-tax charges of approximately $320 million, an unfavorable EPS impact of about $1.55
- Prior full-year 2026 guidance, announced August 6, 2026, did not reflect the Alesta acquisition
- Quarter results are not finalized and figures are preliminary and unaudited
Read the filing on SEC.gov ↗
Sep 30, 4:15 PM ET
BioMarin entered into a Settlement and License Agreement with Ascendis Pharma on September 24, 2026, replacing an August 2026 binding term sheet. Ascendis receives a non-exclusive license to BioMarin patents covering TransCon CNP (navepegritide, Yuviwel), and BioMarin receives royalties on net sales until May 2030. The filing says the parties will dismiss all pending litigation between them over the patents, and it does not disclose dollar amounts.
- Agreement dated September 24, 2026, deemed effective August 28, 2026, and supersedes the term sheet reported on August 31, 2026
- Royalty of 20% of annual net sales in the United States and 18% in the EU, Brazil and South Korea, until May 2030
- Pending litigation between the parties relating to the BioMarin patent rights to be dismissed with prejudice
- Ascendis agreed not to challenge BioMarin's patent rights; no dollar figures disclosed
Read the filing on SEC.gov ↗
Sep 14, 9:26 AM ET
BioMarin's board increased its size from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., as an independent non-employee director effective September 10, 2026. Dr. Plenge also joins the board's Science and Technology Committee, and his director pay includes a restricted stock unit grant valued at $400,000.
- Board expanded from ten to eleven members; Dr. Plenge appointed effective September 10, 2026
- Dr. Plenge joins the Science and Technology Committee
- Restricted stock unit grant valued at $400,000, vesting on the date immediately before the next annual meeting
- Company intends to sign a standard indemnification agreement with Dr. Plenge
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
